Biosimilars: FDA Casts Wide Net For Creation Of User Fees
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency seeks "consultation meetings" with patient, consumer, professional and academic groups as it develops congressionally-mandated report on the nascent approval pathway.